Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23562801 | 0.92 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL25280336 | 0.86 | EGLN1 (0.77) | EGLN1 | |
| SCHEMBL25278826 | 0.83 | EGLN1 (0.69) | EGLN1 | |
| SCHEMBL31050996 | 0.83 | EGLN1 (0.69) | EGLN1 | |
| Glycine SCHEMBL28393884 | 0.80 | EGLN1 (0.73) | EGLN1 | |
| SCHEMBL28639485 | 0.78 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL24257551 | 0.77 | EGLN1 (0.70) | EGLN1 | |
| SCHEMBL28395558 | 0.75 | EGLN1 (0.76) | EGLN1 | |
| SCHEMBL24257803 | 0.74 | EGLN1 (0.57) | EGLN1 | |
| SCHEMBL28657491 | 0.71 | EGLN1 (0.84) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | IDO1, PDCD1, IDO2 | EGLN1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.